Новые подходы в лечении хронического лимфолейкоза

А Б Бакиров, Б. А. Бакиров · Медицинский вестник Башкортостана · 2007

In the last 10 year purine analogs have become the chemotherapy of choice for the first-line treatment of chronic lymphocytic leukemia, principally because of their superior efficacy compared with alkylating agents. Fludarabin-based combination chemotherapy regimens were well tolerated and can be delivered safely to older patients. Several clinical trials have shown the efficacy of monoclonal antibodies: alemtuzumab and rituximab. Current studies indicate that treatment with monoclonal antibodies can achieve remissions with undetectable residual disease. Alemtuzumab and rituximab used in combination with chemotherapeutics or immunotherapeutics. New treatment regimens, including combinations of monoclonal antibodies, could enhance complete response rates and prolong progression-free survival, perhaps eventually improving our ability to cure patients with lymphocytic leukemia.

Cited by 0 works.

Authors